Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome

Trial Profile

Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs ARQ 092 (Primary)
  • Indications Proteus syndrome
  • Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 20 Jan 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
    • 20 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.
    • 07 Nov 2016 According to ArQule media release, assessment of full data from the initial two cohorts will be in the early part of next year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top